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As part of the Spare-the-Nephron trial, we evaluated the
combination mycophenolate mofetil (MMF) and sirolimus
(SRL) as a calcineurin inhibitor (CNI)-free regimen for the
preservation of renal function in renal allograft recipients.
This 2-year, open-label, multicenter trial randomized 299
patients of which 151 were maintained on MMF and a CNI,
148 on MMF plus SRL (n¼ 120, tacrolimus; n¼ 31,
cyclosporine). Baseline characteristics including measured
(iothalamate) glomerular filtration rate (GFR) were similar
between groups. After 1 year, the mean percentage change
from baseline in the primary end point of measured GFR was
significantly higher in the MMF/SRL group compared with
the MMF/CNI group. After 2 years, the change was
indistinguishable. Calculated creatinine clearance and GFR
were significantly greater with MMF/SRL at 2 years within
which biopsy-proven acute rejection (BPAR) occurred in 14
MMF/SRL-treated patients (3 graft losses) and in 17 receiving
the MMF/CNI (6 graft losses). Significantly, no patients
receiving MMF/SRL but five treated with MMF/CNI died. Thus,
compared with MMF/CNI treatment, a 2-year regimen of
MMF/SRL resulted in similar measures of renal function but
with fewer deaths and a trend to less BPAR and graft loss.
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The use of calcineurin inhibitors (CNIs) in renal transplanta-
tion has dramatically reduced the risk of acute rejection and
has resulted in improvements in early graft survival.1
However, improvements in acute rejection rates do not seem
to correlate well with graft loss and have not resulted in
improvements in long-term graft survival.2 Exposure to CNIs
is often associated with progressive renal dysfunction, a
consequence of both acute nephrotoxicity related to intra-
renal vasoconstriction and direct toxicity that results in
allograft nephropathy characterized by arteriolar hyalinosis,
interstitial fibrosis, and tubular atrophy.3,4
Mycophenolate mofetil (MMF) and sirolimus (SRL) are
immunosuppressive agents that have been associated with
lesser degrees of nephrotoxicity5 compared with CNIs when
used alone or together in long-term studies.6 MMF, a
reversible inosine monophosphate dehydrogenase inhibitor,
blocks the proliferation of lymphocytes and decreases
inflammation7 and was shown to significantly reduce the
risk of chronic renal allograft failure.8 SRL is an inhibitor of
the mammalian target of rapamycin, a key kinase involved in
T-lymphocyte activation and proliferation.9 Taken together,
these agents may offer a complementary immunosuppressive
strategy with the potential for delaying or preventing pro-
gressive renal allograft dysfunction.5
Conversion from a CNI-based regimen to a combination
of MMF and SRL has recently been investigated as a rescue
strategy for patients with deteriorating renal function due to
chronic allograft nephropathy; these studies have demon-
strated conflicting results in terms of improved graft
function.10–12 The CONVERT trial13 findings indicated that
improved graft function occurs in patients with estimated
glomerular filtration rates (GFRs) above 40ml/min and a
urine protein:creatinine ratio o0.1. In addition to studies of
patients with deteriorating renal function, several studies
have evaluated de novo maintenance regimens in which the
efficacy and safety of the combination of MMF/CNI were
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compared with those of MMF/SRL; most of these studies
reported improved renal function in the MMF/SRL arm,14–17
although one study involving tacrolimus reported no
significant difference.18 The de novo use of lower-dose SRL
(trough target range, 4–8mg/ml) in combination with MMF
has resulted in an increased risk of acute rejection, treatment
failure, and reduced allograft survival compared with MMF/
tacrolimus.19 In a recently published randomized study in
which patients were converted to SRL at 3 months or main-
tained on cyclosporine, both in combination with MMF,
patient and graft survival were not significantly different, but
patients on the SRL regimen had improved renal function at
the end of 1 year.20 These studies demonstrate the feasibility
of long-term CNI-free maintenance with MMF in combina-
tion with SRL. To further test this hypothesis, this study
evaluated the long-term impact of MMF and SRL in patients
who had been withdrawn from a CNI early after transplant.
RESULTS
Patient enrollment and baseline characteristics
This multicenter, open-label study (Figure 1) was conducted
between August 2003 and November 2008. A total of 305
patients were randomized. The intent-to-treat (ITT) popula-
tion included 299 patients; 3 patients who were originally
randomized to receive MMF/SRL did not receive therapy and
were only included in the MMF/CNI group for safety
analysis, and 3 patients randomized to the MMF/CNI group
did not receive a postbaseline efficacy assessment and
therefore were not included in the ITT population. The
safety population included 301 patients; 4 patients ran-
domized to receive MMF/CNI had no postbaseline safety
assessment. In the ITT population, 120 of 151 (79%) patients
randomized to the CNI maintenance group (MMF/CNI) had
received tacrolimus before randomization, and 119 of 148
(80%) patients randomized to the CNI withdrawal group
(MMF/SRL) had received tacrolimus before randomization.
The mean time from transplant to randomization was
113.2±53.8 days in the MMF/SRL group and 115.7±49.2
days in the MMF/CNI group. Treatment groups were well
balanced with respect to baseline demographics and clinical
characteristics as well as to baseline measured and calculated
GFR (Table 1). In total, 48 of 148 (32%) African-American
patients receiving MMF/SRL and 50 of 151 (33%) receiving
MMF/CNI (cyclosporine, n¼ 10; tacrolimus, n¼ 40) were
enrolled; treatment groups were similar at baseline for renal
function end points.
Of the 305 randomized patients, 39 (26%) in the MMF/
SRL group and 38 (25%) in the MMF/CNI group prematurely
withdrew during the study treatment period (17 and 15
patients in each group, respectively, were African American).
The majority of withdrawals were for reasons related to safety
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Figure 1 | Trial design. Randomization was prestratified by
calcineurin inhibitor type at screening. MMF, mycophenolate
mofetil; Tx, transplant.
Table 1 | Baseline demographics and clinical characteristics of
patients and donors
MMF/CNI
Characteristic
MMF/SRL
(N=148)
Total
(N=151)
MMF/TAC
(N=120)
Gender, n (%)
Male 93 (62.8) 96 (63.6) 76 (63.3)
Female 55 (37.2) 55 (36.4) 44 (36.7)
Age (years), mean±s.d. 48.7±12.9 48.7±12.7 49.5±12.5
Race, n (%)
Caucasian 74 (50.0) 75 (49.7) 59 (49.2)
African American 48 (32.4) 50 (33.1) 40 (33.3)
Other 26 (17.6) 26 (17.2) 21 (17.5)
Primary reason for renal transplant, n (%)
Hypertension 41 (27.7) 41 (27.2) 32 (26.7)
Diabetes mellitus 33 (22.3) 36 (23.8) 27 (22.5)
Cystic/polycystic kidney
disease
18 (12.2) 19 (12.6) 17 (14.2)
Glomerulonephritis 31 (20.9) 21 (13.9) 16 (13.3)
Pyelonephritis/interstitial
nephritis
1 (0.7) 2 (1.3) 2 (1.7)
Other or uncertain 24 (16.2) 32 (21.2) 26 (21.7)
Donor type, n (%)
Deceased 88 (59.5) 92 (60.9) 72 (60.0)
Living related 41 (27.7) 38 (25.2) 29 (24.2)
Living unrelated 19 (12.8) 21 (13.9) 19 (15.8)
Panel reactive antibody
levels X20%, n (%)
21 (14.2) 28 (18.5) 23 (19.2)
HLA mismatches 30 (20.3)– 15 (9.9)– 9 (7.5)–
(range of 0–6), n (%) 17 (11.5) 18 (11.9) 14 (11.7)
Use of induction therapy, n (%)
Antithymocyte globulin 52 (35.1) 53 (35.1) 44 (36.7)
Basiliximab 35 (23.6) 45 (29.8) 33 (27.5)
Daclizumab 18 (12.2) 14 (9.3) 8 (6.7)
Muromonab-CD3 0 (0.0) 1 (0.7) 1 (0.8)
Total 105 (70.9) 113 (74.8) 86 (71.7)
Patients receiving antiviral
prophylaxis (transplant to
baseline), n (%)
59 (39.9) 62 (41.1) 49 (40.8)
Baseline measured GFR
(ml/min per 1.72 m2), mean±s.d.
59.5±23.9 58.8±26.1 60.5±26.4
African Americans only 61.6±25.8 58.1±27.0 62.2±28.0
Rejection episode before
randomization, n (%)
10 (6.8) 11 (7.3) 8 (6.7)
Abbreviations: CNI, calcineurin inhibitor; GFR, glomerular filtration rate; HLA, human
leukocyte antigen; MMF, mycophenolate mofetil; SRL, sirolimus; TAC, tacrolimus.
P40.05 for the MMF/SRL vs the MMF/CNI groups for all variables is shown.
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(Table 2). There was no difference between treatment groups
in the proportion of patients withdrawing because of
any reason. Overall, 228 patients completed the treatment
at 12 months and 236 completed at 24 months of the study,
regardless of treatment completion. In all, 41 of 148 patients
randomized to the MMF/SRL group switched to MMF/CNI
therapy (35 to tacrolimus) during the study, 2 of 31 patients
randomized to the MMF/CNI group switched from cyclos-
porine to tacrolimus, and 2 of 120 patients randomized to the
MMF/CNI group switched from tacrolimus to cyclosporine.
Immunosuppressant doses and exposure
The mean average daily dose of MMF received by the MMF/
SRL and MMF/CNI groups was similar at baseline
(1895.4±355.0mg and 1889.4±402.2mg, respectively) and
throughout the 24-month period (1645.0±485.2mg and
1627.8±519.3mg, respectively). The mean (±s.d.) average
daily dose of SRL (3.3±1.09mg at month 1 and 2.9±1.3mg
at month 24) was generally consistent throughout the study
whereas the tacrolimus (8.6±5.5mg at month 1 and
7.1±5.2mg at month 24) and cyclosporine doses
(346.7±118.4mg at month 1 and 240.4±75.2 at month
24) showed a trend to decrease over time. Mean mycophe-
nolic acid (MPA) trough concentrations were significantly
higher in the MMF/SRL group (Figure 2a) at 1, 2, and 6
months whereas mean SRL (Figure 2b) and tacrolimus
(Figure 2c) trough levels were generally consistent through-
out the study. Cyclosporine trough levels decreased through-
out the study, reflecting the reduction in dosing (Figure 2d).
Approximately 94% of participants in each of the MMF/SRL
and the MMF/CNI groups received corticosteroids (exclud-
ing treatment for rejection) for at least 1 day, and B64 and
55% of participants in each group, respectively, were still
receiving corticosteroids at 2 years after randomization. The
mean corticosteroid dose (excluding treatment for rejection)
decreased from 9.4±6.9mg and 13.6±52.8mg during the
interval of 1 and 30 days after randomization to 5.6±4.2mg
and 11.1±57.1mg during the 366–730-day interval, for the
MMF/SRL and MMF/CNI groups, respectively.
Efficacy outcomes
In the ITT analysis, at 12 months, patients receiving MMF/
SRL had a significantly greater mean improvement in
measured GFR than did the MMF/CNI group (Figure 3a);
at 24 months after randomization, the mean percentage
change from baseline in measured GFR (a secondary study
end point) remained higher in the MMF/SRL group (8.6%)
than in the MMF/CNI group (3.4%), but the least-squares
mean difference between groups was not significant (Figure
3b). In the per-protocol analysis, the mean percentage change
from baseline at 12 months in measured GFR was 23.2% in
the MMF/SRL group and 4.0% in the MMF/CNI group
(P¼ 0.054), and at 24 months, the mean percentage change
from baseline was 9.8% in the MMF/SRL group and 2.1% in
the MMF/CNI group (P¼ not significant (NS)).
In an exploratory, post hoc analysis that included only
patients with measurements at baseline and both years 1 and
2 (MMF/SRL, n¼ 103; MMF/CNI, n¼ 91), there was a
significant increase in measured GFR from baseline at 12
months in the MMF/SRL group (6.0 (95% confidence
interval: 1.0, 11.0); P¼ 0.02) but not in the MMF/CNI
group (3.0 (9.4, 3.3); P¼NS). At 24 months, there was
no significant change from baseline in measured GFR in the
MMF/SRL group (0.1 (95% confidence interval: 5.1, 4.9);
P¼NS) whereas there was a significant decrease from
baseline in the MMF/CNI group (6.9 (13.3, 0.6);
P¼ 0.03). Measured GFR decreased in both the MMF/SRL
and the MMF/CNI groups between years 1 and 2,
significantly so in the MMF/SRL group (6.1 (95%
confidence interval: 11.1,1.1); P¼ 0.02 vs 3.9 (10.2,
2.4); P¼NS, respectively). However, estimated GFR did not
decrease for either group from year 1 to 2.
Table 3 presents the results of other renal function
measures. In the MMF/SRL group, the mean percentage
change from baseline in calculated creatinine clearance was
significantly greater than in the MMF/CNI group at 12 and
24 months, whereas the differences in the mean percentage
change from baseline in calculated GFR and in serum
creatinine levels were not significant at 12 months but were
significant at 24 months.
The percentage of patients with treatment failure at 12 and
24 months after randomization did not differ significantly
between the treatment arms (Table 4). At 12 months, biopsy-
proven acute rejection (BPAR) was reported in 7.4% of
patients in the MMF/SRL group and in 6.0% of patients in
the MMF/CNI group (P¼NS). The rate of late BPAR,
defined as occurring412 months after randomization, was 4
(2.9%) in the MMF/SRL group and 11 (8.0%) in those
receiving MMF/CNI, which included 3 patients receiving
Table 2 | Summary of patients withdrawn during the study
treatment period and reasons for withdrawal, n (%)
Reason for withdrawal*
MMF/SRL
(N=151)
MMF/CNI
(N=154)
MMF/TAC
(N=122)
Safety 29 (19.2) 22 (14.3) 19 (15.6)
Adverse eventa 29 (19.2) 19 (12.3) 17 (13.9)
Death 0 (0.0) 3 (1.9) 2 (1.6)
Nonsafety 10 (6.6) 16 (10.4) 11 (9.0)
Insufficient therapeutic
response
3 (2.0) 1 (0.6) 0 (0.0)
Violation of selection criteria
at entry
4 (2.6) 1 (0.6) 1 (0.8)
Other protocol violation 0 (0.0) 1 (0.6) 1 (0.8)
Refused treatmentb 1 (0.8) 5 (3.2) 5 (4.1)
Failed to return 2 (1.3) 7 (4.5) 4 (3.3)
Other 0 (0.0) 1 (0.6) 0 (0.0)
Total 39 (25.8) 38 (24.7) 30 (24.6)
Abbreviations: CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; SRL,
sirolimus; TAC, tacrolimus.
*P=not significant for between-group comparisons for all reasons: P-value
comparing the two treatment groups (MMF/SRL vs MMF/CNI) was calculated using
the Cochran–Mantel–Haenszel test, stratified by earlier CNI type.
aIncluded intercurrent illness.
bIncluded ‘did not cooperate’ and ‘withdrew consent.’
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cyclosporine (P¼ 0.07). All but one biopsy was classified as
Banff grade IA or IB; the remaining biopsy was grade IIB.
In all but four patients, MPA trough levels drawn at the time
point closest to the rejection episode were in the therapeutic
range. In seven patients, tacrolimus trough levels drawn at
the time point closest to the rejection episode were lower
than 10 ng/ml, whereas SRL and cyclosporine levels were in
the therapeutic range. Five deaths occurred during the 2-year
period in the MMF/CNI group (Table 4). All deaths were
assessed by the investigator as treatment unrelated, except for
one patient receiving cyclosporine who died from urosepsis
on day 253 of the study; this event was assessed as remotely
treatment related. Other deaths that occurred during year 1
were caused by pulmonary embolism, cardiac arrest, and
cerebrovascular accident; one death due to metastatic lung
cancer was reported during year 2.
Safety outcomes
The overall rate of occurrence of adverse events over the
24-month period was similar across the treatment arms, with
X97% of patients experiencing at least one adverse event and
with 485% reporting that the events were unrelated to the
study medication. The majority of patients had mild or
moderate events; however, B27% in both treatment groups
had a severe to life-threatening event. More patients had to
discontinue the protocol-defined regimen during the treat-
ment period because of adverse events in the MMF/SRL
group (19%) compared with the MMF/CNI group (14%)
(Table 2). However, this was not statistically significant.
Common adverse events occurring during both the 12- and
the 24-month intervals are listed by frequency in Table 5.
Hyperlipidemia, the most frequent event, occurred in a
significantly greater number of patients in the MMF/SRL
group than in the MMF/CNI group, as did peripheral edema
and mouth ulcerations. The most frequently reported adverse
events leading to withdrawal from treatment were mouth
ulcerations (n¼ 7), leukopenia (n¼ 2), pneumonia (n¼ 2),
focal segmental (n¼ 2), and proteinuria (n¼ 3) in the MMF/
SRL group, and polyomavirus (BK) infection (n¼ 4),
diarrhea (n¼ 4), leukopenia (n¼ 4), blood glucose increase
(n¼ 2), and alopecia (n¼ 2) in the MMF/CNI group.
The overall frequency of opportunistic infections at 12 and
24 months was similar in the two treatment groups (Table 6).
CMV (cytomegalovirus) infection was reported in 4.7 and
9.8% of patients in the MMF/SRL and MMF/CNI groups,
respectively, over the 24-month period (P¼ 0.09). Approxi-
mately 40% of patients in each treatment group were
MMF/SRL
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Figure 2 | Immunosuppresion medication levels during
follow-up. (a) Mycophenolic acid (MPA); (b) sirolimus (SRL);
(c) tacrolimus (TAC); and (d) cyclosporine (calcineurin inhibitor
(CNI) for both) trough levels from baseline to month 24. P-value is
for mycophenolate mofetil (MMF)/SRL vs MMF/CNI using analysis
of variance adjusting for baseline CNI type. MPA trough levels
47000 or o100 ng/ml, and records after a patient switched CNI
regimen (for the MMF/CNI group) or switched back to a CNI
regimen (for the MMF/SRL group) were excluded.
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receiving antiviral agents for prophylaxis at baseline (Table 1).
BK virus infection was reported in 0 and 5.9% (P¼ 0.003) of
patients in the MMF/SRL and MMF/CNI groups, respectively
(Table 6).
The mean (±s.d.) 24-h urinary protein:creatinine
ratios were similar in the two treatment groups at baseline
(MMF/SRL, 0.2±0.38, n¼ 126; and MMF/CNI, 0.2±0.23,
n¼ 128), but were significantly different at 12 months
(P¼ 0.004; MMF/SRL, 0.6±1.31, n¼ 107; and MMF/CNI,
0.4±1.07, n¼ 110). Nephrotic syndrome occurred in one
patient in the MMF/SRL treatment group. At 24 months, the
mean 24-h urinary protein:creatinine ratios were 0.6±1.89
(n¼ 107) and 0.2±0.54 (n¼ 86) in the MMF/SRL and
MMF/CNI treatment groups, respectively (P¼ 0.001).
Before randomization, 121 of 148 (81.8%) patients in the
MMF/SRL group and 125 of 153 (81.7%) patients in the
MMF/CNI group were categorized as hyperlipidemic
(P¼NS). During the study, a significantly greater number
of patients in the MMF/SRL group were reported as having
either new-onset or worsening hyperlipidemia (120/148
(81.1%) vs 97/153 (63.4%); Po0.001). There was a mean
increase from baseline in total cholesterol and low-density
lipoprotein (LDL) cholesterol in the MMF/SRL group at both
12 and 24 months after randomization. Accordingly, the
change from baseline at 12 and 24 months in total cholesterol
levels (and LDL levels) in patients receiving MMF/SRL was
significantly higher than in patients receiving MMF/CNI
(Table 7) whereas the change from baseline in triglycerides
and LDL/high-density lipoprotein ratios was comparable
between groups. This trend continued into the 24-month
assessment for LDL/high-density lipoprotein ratios, but the
change in mean triglyceride level was significantly higher in
the MMF/SRL group (P¼ 0.01) at year 2 (Table 7). Similarly,
the use of lipid-regulating agents after randomization was
significantly greater in patients receiving MMF/SRL (79.1%)
than in those receiving MMF/CNI (59.5%; Po0.001) having
increased in both groups from pre-randomization use (48.6
and 40.5%, respectively).
Before randomization, 99 of 148 (66.9%) patients in the
MMF/SRL group and 97 of 153 (63.4%) patients in the
MMF/CNI group had diabetes mellitus (P¼NS). New-onset
diabetes (including newly reported adverse events of diabetes
mellitus or hyperglycemia, more than one occasion of blood
glucose levels X126mg/dl, and/or new use of antidiabetic
agents for 430 consecutive days) 12 months after randomi-
zation was reported in 11 (11.1%) and 14 (14.4%; P¼NS) of
patients in each group, respectively.
There was no difference in the change from baseline in
systolic blood pressure between the treatment groups at 12 or
24 months; however, at 12 months, the mean diastolic blood
pressure level increased in the MMF/CNI group and
decreased in the MMF/SRL group, and by 24 months, the
change in diastolic blood pressure was significantly different
between the two groups (P¼ 0.02). There was no difference
between treatment groups in the use of antihypertensives
overall before randomization (90.5% in the MMF/SRL group
and 87.6% in the MMF/CNI group), but there was a
significantly greater use for new or worsening hypertension
after randomization in the MMF/SRL group (68.2 vs 50.3%,
respectively; P¼ 0.002). During the study, 31 and 30% of
patients in the MMF/SRL group and 29 and 21% of patients
in the MMF/CNI group were treated with angiotensin-
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Figure 3 |Changes in measured GFR during follow-up. Mean
change in measured glomerular filtration rate (GFR; cold
iothalamate) stratified by treatment group from baseline to (a)
month 12 and (b) month 24 in all patients with nonmissing
measurements at baseline and 12 months. *P-value comparisons
were calculated using analysis of covariance with treatment and
calcineurin inhibitor (CNI) type as factors, and baseline
measurement and time from transplant to randomization as
covariates. If a measurement was within a dialysis medication
period, the GFR value was below 15ml/min (one patient met this
criterion), or with graft loss, the GFR was imputed as 15ml/min.
Records4150ml/min were excluded; this included six patients in
the mycophenolate mofetil (MMF)/CNI group. *Tacrolimus (TAC)
withdrawal vs MMF/TAC: P¼ 0.02; all others were not significant.
SRL, sirolimus.
Kidney International (2011) 79, 897–907 901
MR Weir et al.: Spare-the-Nephron trial in kidney transplants o r ig ina l a r t i c l e
converting enzyme inhibitors and angiotensin-II receptor
antagonists, respectively.
DISCUSSION
This prospective, randomized, controlled, open-label trial
was designed to test the hypothesis that renal transplant
recipients who are withdrawn from CNI-based therapy early
after transplantation and maintained on MMF in combina-
tion with SRL will have improved 1-year measured GFR.
As 1-year renal function is such an important predictor of
long-term graft function1 and cardiovascular event-free
survival,21 it is important to identify safe and effective forms
of immunosuppression that may allow improved kidney
function in the first year after transplantation.
In this trial, patients who were maintained on MMF/CNI
for p6 months and then converted to maintenance immuno-
suppression with MMF/SRL had greater improvement in
measured GFR than did those patients remaining on MMF/
CNI. Changes from baseline in measured GFR and calculated
creatinine clearance were significantly greater 12 months after
conversion in those patients who had CNI withdrawn. This
improvement in GFR was achieved without any increase in
the risk of BPAR or treatment failure in the CNI withdrawal
group. The improvement in measured GFR persisted 2 years
Table 3 | Changes in calculated GFR, serum creatinine, and calculated creatinine clearance from baseline to months 12 and 24
Overall population
MMF/SRL
(N=148)
MMF/CNI
(N=151)
MMF/SRL
(TAC withdrawal) (N=122)
MMF/TAC
(N=120)
MMF/SRL vs
MMF/CNI*
TAC withdrawal vs
MMF/TAC*
Calculated GFR, ml/min
Baseline, mean±s.d. 71.3±13.8 72.7±16.2 71.2±14.1a 74.1±16.6
Month 12, mean±s.d. 74.6±17.9 71.5±21.2 74.1±17.8 72.7±21.2
% Change, baseline to month 12 (n) 5.2±25.3 (123) 0.9±23.4 (123) 4.9±26.2 (103) 2.0±22.3 (96) 0.06 0.09
Month 24, mean±s.d. 75.5±19.2 71.2±23.5 74.8±19.7 72.6±23.5
% Change, baseline to month 24 (n) 6.5±28.4 (120) 1.8±27.3 (116) 6.3±29.5 (102) 2.4±26.0 (92) 0.04 0.08
Serum creatinine, mmol/l
Baseline, mean±s.d. 121.1±30.0 124.4±37.9 121.3±30.5 121.6±38.7
Month 12, mean±s.d. 126.2±82.8 145.0±96.5 128.8±89.4 142.7±96.2
% Change, baseline to month 12 (n) 6.0±57.8 (124) 20.4±92.8 (123) 7.7±62.3 (103) 20.4±89.4 (96) 0.11 0.23
Month 24, mean±s.d. 127.1±83.9 151.8±117.0 130.0±90.3 146.1±110.0
% Change, baseline to month 24 (n) 6.1±59.8 (120) 30.8±114.2 (116) 7.5±64.1 (102) 28.6±108.6 (92) 0.04 0.12
Calculated creatinine clearance, ml/min
Baseline, mean±s.d. (n) 59.7±16.9 60.5±20.0 59.0±16.5 61.7±20.6
Month 12, mean±s.d. 61.9±20.1 58.0±23.3 60.6±19.3 59.3±23.8
% Change, baseline to month 12 (n) 4.4±2443 (124) 2.3±25.1 (123) 3.7±24.7 (103) 3.1±24.4 (96) 0.03 0.07
Month 24, mean±s.d. 62.3±22.1 56.9±23.0 60.9±20.7 58.5±23.3
% Change, baseline to month 24 (n) 4.7±27.6 (120) 4.2±27.7 (116) 4.5±28.2 (102) 4.2±26.4 (92) 0.02 0.04
Abbreviations: ANCOVA, analysis of covariance; CNI, calcineurin inhibitor; GFR, glomerular filtration rate; MMF, mycophenolate mofetil; SRL, sirolimus; TAC, tacrolimus.
*P-value comparing the two treatment groups (MMF/SRL vs MMF/CNI) is from ANCOVA model with terms for treatment and CNI type, and baseline measurement and time
from transplant to randomization as covariates.
aN=116.
Table 4 | Secondary efficacy analyses at 12 and 24 months
12 Months 24 Months
MMF/SRL
(N=148)
MMF/CNI
(N=151)
MMF/TAC
(N=120)
MMF/SRL
(N=148)
MMF/CNI
(N=151)
MMF/TAC
(N=120)
Treatment failurewa 36 (24.3) 29 (19.2) 25 (20.8) 50 (33.8) 42 (27.8) 35 (29.2)
95% CI for treatment failure 17.7, 32.1 13.3, 26.4 14.0, 29.2 26.2, 42.0 20.8, 35.7 21.2, 38.2
Reasons for treatment failure
Death 0 (0.0) 3 (2.0) 2 (1.7) 0 (0.0) 4 (2.6) 3 (2.5)
Graft loss 0 (0.0) 1 (0.7) 1 (0.7) 0 (0.0) 2 (1.3) 1 (0.8)
Withdrawal due to adverse event 24 (16.2) 11 (7.3) 9 (7.5) 28 (18.9) 12 (7.9) 10 (8.3)
Need to resume CNI 5 (3.4) 0 (0.0) 0 (0.0) 7 (4.7) 0 (0.0) 0 (0.0)
Need to withdraw therapy 4 (2.7) 8 (5.3) 8 (6.7) 6 (4.1) 9 (6.0) 9 (7.5)
Lost to follow-up 2 (1.4) 6 (4.0) 5 (4.2) 7 (4.7) 15 (9.9) 12 (10.0)
Withdrew consent 1 (0.7) 0 (0.0) 0 (0.0) 2 (1.4) 0 (0.0) 0 (0.0)
Biopsy-proven acute rejection, n (%)w 11 (7.4) 9 (6.0) 7 (5.8) 14 (9.5) 17 (11.3) 14 (11.7)
Graft lossw 3 (2.0) 4 (2.6) 3 (2.5) 3 (2.0) 6 (4.0) 4 (3.3)
Death (safety population)w 0 (0.0) 3 (2.0) 2 (1.7) 0 (0.0) 5 (3.3)z 4 (3.3)
Abbreviations: CI, confidence interval; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; SRL, sirolimus; TAC, tacrolimus.
wP=not significant for all comparisons at both 12 and 24 months, except if otherwise noted; P-value comparing the two treatment groups for treatment failure (MMF/SRL vs
MMF/CNI), and biopsy-proven acute rejection was calculated using the Cochran–Mantel–Haenszel test stratified by CNI type. For graft loss, P-value is from the w2-test. Each
event is counted.
zPp0.03.
95% CI is calculated using exact method.
aEvents are mutually exclusive because only first event was counted for each patient.
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after conversion in the MMF/SRL group but was not
statistically significant in comparison with the MMF/CNI
group because of combined factors, including withdrawal of
patients receiving MMF/SRL who had improvements, switch-
ing of patients to CNI treatment, tapering of CNI doses, and
greater variation in measurements. As 41 patients were
switched back from MMF/SRL to MMF/CNI, we suspect that
this may be the main reason for the lessening of the
improvement in GFR later in the study. Both at 1 and 2 years
after randomization, there were fewer deaths and graft losses
in the MMF/SRL group (Po0.03). These observations have
important clinical implications.
The Spare-the-Nephron trial was designed to allow center-
specific approaches for choice and dose of induction
immunosuppression, CNIs, and corticosteroids. The only
study requirement was that participants be maintained, if
possible, on at least 2 g of MMF per day. This clinical trial
design provided a more practical and realistic approach to
evaluate this type of early conversion strategy, given the many
different center-specific approaches to both induction and
chronic immunosuppression.
Although the findings of the very large, multinational,
ELITE (Efficacy Limiting Toxicity Elimination)-Symphony
study19 were similar to those of our study in that there were
no improvements in measured GFR with the low-dose
tacrolimus group compared with the low-dose SRL group
(it must be noted that these ‘low-dose’ levels were similar to
those in our study), SRL was associated with a signifi-
cantly higher rate of BPAR (40%) vs tacrolimus (15%) at
12 months. This difference may have been due to the study
design; in the ELITE-Symphony study, SRL was initiated
de novo in contrast to our study in which patients were
maintained on CNIs for at least 30 days, and the SRL target
levels for this study were lower than those for all other
previous studies. In addition, our study excluded patients
who immunologically failed their initial regimen.
The characteristics of patients participating in this clinical
trial reflect individuals who are at somewhat higher risk for
acute rejection as approximately a third of the patients were
of African-American descent and 415% had panel-reactive
antibody levels 420%. This may explain why, with our
center-specific approach, trough tacrolimus and cyclosporine
levels were somewhat higher than those that some studies19
have incorporated. The efficacy and safety of this
early conversion approach were consistent regardless of
baseline risk for acute rejection, as non-African-American
and African-American participants had similar rates of
acute rejection irrespective of whether they were converted
Table 5 | Selected adverse events reported after randomization, n (%)a
12 Months 24 Months
Adverse event
MMF/SRL
(N=148)
MMF/CNI
(N=153)
MMF/TAC
(N=121)
MMF/SRL
(N=148)
MMF/CNI
(N=153)
MMF/TAC
(N=121) P-valuew
Hyperlipidemiab 36 (24.3) 16 (10.5) 12 (9.9) 120 (81.1) 97 (63.4) 77 (63.6) 0.0007
Diarrhea 44 (29.7) 39 (25.5) 31 (25.6) 51 (34.5) 50 (32.7) 41 (33.9) 0.79
Peripheral edema 32 (21.6) 15 (9.8) 11 (9.1) 42 (28.4) 20 (13.1) 16 (13.2) 0.001
Leukopenia 36 (24.3) 28 (18.3) 25 (20.7) 36 (24.3) 29 (19.0) 26 (21.5) 0.28
Hypertension 25 (16.9) 20 (13.1) 14 (11.6) 30 (20.3) 25 (16.3) 18 (14.9) 0.37
Mouth ulceration 21 (14.2) 0 (0) 0 (0) 21 (14.2) 0 (0.0) 0 (0.0) o0.0001
Malignanciesc 7 (4.7) 10 (6.5) 7 (5.8) 7 (4.7) 10 (6.5) 7 (5.8) 0.51
Abbreviations: CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; SRL, sirolimus; TAC, tacrolimus.
wP-value comparing the two treatment groups (MMF/SRL vs MMF/CNI) was calculated using the Cochran–Mantel–Haenszel test stratified by earlier CNI type.
aSafety population included patients who received X1 dose of study medication.
bDefined as the use of any lipid-lowering drugs or lipid laboratory abnormality (total cholesterol4210mg/dl, triglycerides4200mg/dl, low-density lipoprotein4100mg/dl
or high-density lipoprotein o30mg/dl) after day 1.
cMalignancies counting patients only.
Table 6 | Opportunistic infections (OIs) at 12 and 24 months after randomization, n (%)
Up to 12 months Up to 24 months
MMF/SRL
(N=148)
MMF/CNI
(N=153)
MMF/TAC
(N=121)
MMF/SRL
(N=148)
MMF/CNI
(N=153)
MMF/TAC
(N=121)
Total patients with at least one OI 24 (16.2) 28 (18.3) 23 (19.0) 28 (18.9) 34 (22.2) 28 (23.1)
Aspergillus 0 (0.0) 1 (0.7) 1 (0.8) 0 (0.0) 1 (0.7) 1 (0.8)
BK virus infection 0 (0.0) 4 (3.0)* 3 (2.0) 0 (0.0) 9 (5.9)* 7 (5.8)
Candida 6 (4.1) 8 (5.2) 5 (4.1) 8 (5.4) 12 (7.8) 8 (6.6)
Cytomegalovirus 7 (4.7) 14 (9.2)w 12 (9.9) 7 (4.7) 15 (9.8)w 13 (10.7)
Herpes simplex 6 (4.1) 1 (0.7) 1 (0.8) 6 (4.1) 1 (0.7) 1 (0.8)
Herpes zoster 8 (5.4) 7 (4.6) 7 (5.8) 12 (8.1) 8 (5.2) 8 (6.6)
Pneumocystis 2 (1.4) 0 (0.0) 0 (0.0) 2 (1.4) 0 (0.0) 0 (0.0)
Cryptococcus 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.8)
Abbreviations: BK, polyomavirus; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; SRL, sirolimus; TAC, tacrolimus.
*Po0.05 for MMF/SRL vs MMF/CNI was calculated using the Cochran–Mantel–Haenszel test, stratified by earlier CNI type.
wP=not significant for MMF/SRL vs MMF/CNI was calculated using the Cochran–Mantel–Haenszel test, stratified by earlier CNI type.
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(data not shown). It is important to note that only two-thirds
of patients received some form of induction therapy and
that the average MMF dose was nearly 2 g throughout
the first and second years with the mean trough SRL levels
consistently B8 ng/ml. This may explain the lower rates of
acute rejection over 2 years compared with other studies. The
mean tacrolimus trough levels at 12 and 24 months were
B8 ng/ml whereas the cyclosporine trough levels were
B100 ng/ml. This low rate of BPAR was comparable with
that reported with the MMF/CNI regimen, despite the
previously mentioned higher-trough CNI levels. Approxi-
mately 74% of transplant recipients were still receiving low-
dose corticosteroids at 12 months after conversion and only
B60% at 2 years after conversion.
The results of this clinical trial demonstrate that conver-
sion from a CNI to SRL in the first few months after
transplant is safe and reasonably well tolerated. However,
there was a difference in the pattern and frequency of adverse
events between those patients converted to SRL and those
remaining on CNI (Table 5). Overall, there were the same
number of treatment failures, but more patients in the SRL
arm had adverse events requiring drug cessation. Although
28% of patients in the MMF/SRL arm switched to MMF/
CNI, no patients receiving MMF/CNI switched to MMF/SRL.
Interestingly, there were changes in the urinary protein:
creatinine ratio in the MMF/SRL group when compared with
the MMF/CNI group. The protein:creatinine ratio increased
from 0.2±0.4 at baseline to 0.6±1.9 at 24 months in the
MMF/SRL group whereas there was no change in the MMF/
CNI group. The clinical significance of this change is
unknown. There were lower rates of CMV and BK infection
in the MMF/SRL group than in the MMF/CNI group. The
explanation for this reduced rate of viral infection is unknown.
The results from our early conversion of CNI to SRL with
MMF are comparable with those of the CONCEPT Study,20
with clinically relevant improvement in GFR at 1 year after
conversion, and are somewhat different than data for later
conversion of patients who had already started to experience
graft dysfunction or had increasing amounts of proteinuria.
Compared with the CONCEPT Study, our data provide 2
years of follow-up with measured GFR as opposed to
estimated GFR and use a center-specific approach to
immunosuppression rather than a specific protocol involving
induction, CNI choice, and steroid withdrawal. Thus, it has
broader clinical applicability.
Diekmann et al.22 noted that in patients with proteinuria
4800mg, conversion to SRL was associated with a marked
increase in urinary protein. Wali et al.12 found that the earlier
the conversion from CNI to SRL was completed in the post-
transplant period, the better the outcome in terms of
preserving kidney function and maintaining graft function.
In the CONVERT trial,13 it was quite clear that conversion
in patients with an estimated GFR below 40ml/min was
problematic and that few patients demonstrated an improve-
ment in kidney function. The variability of the results on
kidney function reported in these conversion studies from
CNI to SRL may reflect the heterogeneity of disease of late
allograft dysfunction as some of the patients may have
had smoldering rejection whereas others may have had
recurrent glomerular kidney disease, or CNI nephrotoxicity.
Table 7 | Lipids and blood pressure measurements at
baseline, 12 months, and 24 months
MMF/SRL
(N=148)
MMF/CNI
(N=151)
MMF/TAC
(N=120) P-value*
Total cholesterol, mmol/l
Mean baseline (s.d.) 4.7 (1.04) 5.0 (1.15) 4.9 (1.14)
N 136 140 110
Mean 12 months 5.1 (1.15) 4.6 (1.17) 4.6 (1.06)
N 117 116 91
Change from baseline 0.3 (1.21) 0.4 (1.38) 0.3 (1.3) 0.001
N 110 107 83
Mean 24 months (s.d.) 5.1 (1.28) 4.4 (1.16) 4.3 (1.04)
N 115 106 84
Change from baseline 0.4 (1.36) 0.6 (1.29) 0.6 (1.09) 0.013
N 107 98 77
Triglycerides, mmol/l
Mean baseline (s.d.) 1.8 (0.86) 1.8 (0.97) 1.8 (0.98)
N 134 138 108
Mean 12 months 2.3 (1.66) 2.0 (1.35) 1.8 (0.95)
N 117 116 91
Change from baseline 0.5 (1.71) 0.2 (1.34) 0.0 (0.98) 0.734
N 108 106 82
Mean 24 months (s.d.) 2.5 (2.24) 1.8 (1.80) 1.5 (0.75)
N 114 106 84
Change from baseline 0.6 (2.08) 0.0 (1.67) 0.2 (0.91) 0.013
N 104 97 76
LDL/HDL ratio
Mean baseline (s.d.) 1.9 (0.91) 2.1 (0.92) 2.0 (0.95)
N 129 134 105
Mean 12 months 2.1 (0.97) 2.3 (1.13) 2.3 (1.12)
N 110 110 87
Change from baseline 0.2 (0.83) 0.2 (0.94) 0.2 (0.93) 0.763
N 99 98 76
Mean 24 months (s.d.) 2.2 (1.07) 1.9 (0.79) 1.9 (0.82)
N 105 102 80
Change from baseline 0.3 (1.19) 0.1 (0.79) 0.0 (0.79) 0.457
N 93 91 70
Systolic blood pressure, mmHg
Mean baseline (s.d.) 134.4 (17.31) 134.7 (16.83) 133.0 (15.16)
N 137 141 112
Mean 12 months 135.9 (18.53) 136.6 (20.22) 135.6 (18.80)
N 120 122 96
Change from baseline 1.0 (21.79) 1.7 (22.12) 2.0 (18.87) 0.805
N 111 114 90
Mean 24 months (s.d.) 135.9 (17.16) 136.9 (16.39) 135.9 (14.82)
N 120 107 87
Change from baseline 1.6 (20.97) 2.9 (22.83) 3.7 (19.43) 0.930
N 112 100 82
Diastolic blood pressure, mmHg
Mean baseline (s.d.) 78.6 (10.47) 79.4 (10.23) 79.2 (10.49)
N 137 141 112
Mean 12 months 77.8 (10.01) 80.7 (12.22) 80.3 (11.58)
N 120 122 96
Change from baseline 0.6 (12.01) 1.7 (12.86) 1.0 (12.26) 0.060
N 111 114 90
Mean 24 months (s.d.) 76.7 (10.43) 80.3 (11.35) 80.3 (11.12)
N 120 107 87
Change from baseline 1.6 (11.7) 1.1 (12.31) 1.2 (11.68) 0.019
N 112 100 82
Abbreviations: ANCOVA, analysis of covariance; CNI, calcineurin inhibitor; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; MMF, mycophenolate mofetil; SRL,
sirolimus; TAC, tacrolimus.
*P-value comparing MMF/SRL and MMF/CNI using ANCOVA model with terms for
treatment and calcineurin inhibitor type, time from transplantation to randomiza-
tion, and baseline measurement as a covariate is shown.
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Unfortunately, in our study, data were insufficient to conduct a
post hoc analysis of the change in urinary protein:creatinine
ratio stratified by baseline creatinine clearance or urine protein.
An important unresolved question from our clinical trial
is the explanation for the improvement in GFR. Is this simply
the removal of the CNI? Perhaps more important is the
evidence that within the first and second years after
transplantation, the transplant kidneys can have measurable
improvements in GFR. Other investigators have previously
demonstrated that immunosuppression manipulation in the
first year after transplantation does result in improvement
in 1-year estimated GFR.23 Given the evidence that 1-year
serum creatinine is important in predicting cardiovascular
death and graft survival,1 and is a surrogate marker of graft
loss, it is of clinical importance to develop safe and effective
immunosuppression strategies that will allow enhanced
kidney function in the first year after transplantation. This
improvement in GFR may translate into better patient and
graft longevity.
The 2-year results after randomization do indicate better
patient and graft survival in patients who were converted
from the traditional MMF/CNI regimen to the MMF/SRL
regimen. However, this observation needs to be balanced by
individual tolerability of the medications and increases in
lipids and proteinuria. Longer-term observation will be
required to test the durability of this immunosuppression
manipulation on graft and patient survival.
MATERIALS AND METHODS
Study design and patient selection
This 2-year trial was conducted in 35 transplant centers in the
United States. Male and female patients between 18 and 75 years of
age who were recipients of a primary renal allograft from a living or
deceased donor within the preceding 30–180 days were eligible for
enrollment. Table 8 presents additional inclusion and exclusion
criteria. The study protocol was reviewed and approved by an
Institutional Review Board at each study site and was conducted in
full conformance with the principles of the Declaration of Helsinki.
All study participants provided signed informed consent previous to
randomization. The study is listed on http://www.clinicaltrials.gov
(NCT00118742).
Randomization and treatment
A screening exam was performed from 7 days before transplant to
180 days after transplant. Within 30–180 days after transplant,
eligible patients were randomized in a 1:1 ratio either to maintain
the center-specific CNI choice or to undergo CNI withdrawal.
Patients were pre-stratified into groups according to whether they
were receiving cyclosporine or tacrolimus at the time of randomiza-
tion (Figure 1). Randomization numbers were generated in blocks
with equal treatment allocation in each block. The study sponsor
generated the subject randomization numbers that were accessible
through an interactive voice–response system.
Patients in the CNI withdrawal arms were completely withdrawn
from CNIs within 72 h of randomization; in the CNI maintenance
group, the CNI was dosed according to each center’s protocol.
This was followed by a 2–10mg loading dose of SRL at least 2mg
once daily adjusted to maintain whole-blood trough levels of
5–10 ng/ml. All patients continued to receive 1–1.5 g of MMF twice
daily, and corticosteroids were administered according to center
practice consistently across all study arms. Additional medications
to treat underlying or concurrent diseases or adverse events were
administered at the investigator’s discretion.
Study assessments and end points
At the screening visit, a complete history, MPA trough level, and
blood chemistry analyses were performed. Abbreviated MPA area
Table 8 | Inclusion/exclusion criteria
Inclusion criteria Exclusion criteria
K Maintained on
mycophenolate mofetil
(MMF) and a calcineurin
inhibitor with or without
corticosteroids 14 days
before randomization
K Corticosteroid-resistant, biopsy-
proven acute rejection (BPAR)
episode or treatment for acute
rejection o90 days before
randomization
K No known contraindication
to sirolimus (SRL)
K Corticosteroid-sensitive acute
rejection episode o30 days
before randomization
K Women of childbearing
potential: negative serum
pregnancy test o1 week
before receipt of study
medication; not breast-
feeding; using two reliable
forms of contraception
before, during, and for
12 weeks after the study
K 41 BPAR episode before
enrollment
K Other organ transplants
K Serum creatinine 42.5mg/dl and/
or estimated creatinine clearance
(Cockcroft–Gault) o30ml/min at
randomization
K Inability to provide urine
specimens
K Allergy to cold iothalamate or
iodine
K If received SRL: not being treated
with corticosteroids, or receiving
MMF o1 g twice daily unless
mycophenolic acid area under the
plasma concentration–time curve
of 30–60mg .hr/l was adequate
after receiving the same MMF dose
for X7 days before its
determination
K Severe diarrhea/other
gastrointestinal disorders that
might interfere with absorption,
active peptic ulcer diseases,
diabetic gastroenteropathy, active
systemic infection requiring
antibiotics, HIV, chronic active
hepatitis B or C
K Malignancy in previous 5 years
(except successfully treated
localized nonmelanomatous skin
cancer)
K Hemoglobin o8 g/dl; white blood
count o4000/mm3; platelet count
o100,000/mm3
K Total cholesterol 4300mg/dl;
triglycerides 4350mg/dl
K Receiving dialysis at study entry
K Receiving experimental
immunosuppressive agents or
necessary treatment with
azathioprine, methotrexate,
cyclophosphamide, everolimus, or
enteric-coated mycophenolic acid
sodium
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under the concentration-time curve (AUC)24 was also assessed
during this visit and within 14 days of randomization in patients not
receiving corticosteroids or receiving o1 g of MMF twice daily;
analysis was performed by a central laboratory. Maintenance on the
same dose of MMF for at least 7 days before AUC determination was
necessary. On the day of randomization, on days 7, 14, 30, and 60,
and at months 2, 6, 12, and 24, MPA, SRL, and CNI (except on days
30 and 60) trough levels were measured, and clinical and laboratory
evaluations (including a complete blood count with differential and
a chemistry panel) were performed. Trough levels were also drawn if
acute rejection was suspected. SRL doses were adjusted to maintain
target trough levels. Assay methods were center specific. Renal
function assessments included GFR measured by renal clearance
of cold iothalamate assayed by capillary electrophoresis,25 and urine
protein/creatinine levels were performed at randomization and at
the 12- and 24-month visits. Estimated GFR (Nankivell), estimated
creatinine clearance (Cockcroft–Gault), fasting lipid profiles, and
C-reactive protein were assessed at randomization and at 6, 12,
and 24 months.
The primary efficacy end point was the treatment difference in
the mean percentage change in renal function from baseline to 12
months after randomization as measured by GFR (renal clearance of
cold iothalamate). Secondary efficacy end points included (for each
treatment group) the mean percentage change from baseline in
measured GFR at 24 months and the mean percentage change from
baseline to 12 and 24 months in estimated GFR, estimated creatinine
clearance, and serum creatinine levels. Additional 12- and 24-month
end points included the proportion of patients experiencing BPAR;
the time to first BPAR episode from the date of randomization; the
total number of BPAR episodes per patient; the proportion of
patients with graft loss (defined as the initiation of chronic dialysis
(at least 6 consecutive weeks in duration), transplant nephrectomy,
retransplantation, or death); the proportion of patient deaths; mean
changes in lipid levels and blood pressure, need for antihyper-
tensive or lipid-lowering medications, and proportion of patients
with new-onset diabetes mellitus; and the proportion of patients
with treatment failure, defined as patient death, graft loss, adverse
events leading to premature withdrawal or lost to follow-up, or the
need to resume (group 1) or discontinue (group 2) CNI therapy for
a total of X15 consecutive days or X30 cumulative days, or return
to dialysis for X6 consecutive weeks. Diagnosis of BPAR was based
on clinical signs and symptoms and was confirmed histologically
using the 1997 Banff classification criteria.26 Time to graft loss,
death, or first acute rejection was calculated from the date of
randomization.
Adverse events, including hyperlipidemia, malignancies, diabetes
mellitus and opportunistic infections, and premature withdrawal
due to adverse events were assessed at all visits. A patient was
considered hyperlipidemic if he or she (1) had active disease at the
time of diagnosis or adverse event with preferred terms of
hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, or dys-
lipidemia; (2) had a total cholesterol level 4210mg/dl, triglyceride
level 4200mg/dl, LDL level 4100mg/dl, high-density lipoprotein
level o30mg/dl; or (3) was receiving a lipid-lowering drug.
Statistical analyses
The ITT population included all randomized patients who received
at least one dose of both assigned study medications and who had at
least one postbaseline observation. The safety population included
all randomized patients who received at least one dose of assigned
study medication and who had at least one postbaseline safety
assessment. The per-protocol population was a subgroup of the ITT
population who met all study entry criteria and who received at least
30 days of assigned treatment.
Descriptive statistics were calculated for demographic and
baseline variables for the ITT population. For continuous variables,
the ANOVA/ANCOVA (analysis of variance/analysis of covariance)
model was used to test for the treatment effect. The ANOVA/
ANCOVA model included treatment, early CNI type, and treatment-
by-early-CNI-type interaction as factors, with baseline measurement
as a covariate and time from transplant to study entry as a second
covariate in the ANCOVA models. The treatment-by-early-CNI-type
interaction term was excluded from the model if the test of inter-
action was not significant at the 0.1 level. The normality assumption
was tested; if the assumption was not met, a nonparametric method
was used or rank ANCOVA was performed. For binary responses,
the generalized Cochran–Mantel–Haenszel test stratified by early
CNI type was used to test for general association with 95%
confidence intervals for the difference in proportions. For ordered
categorical variables, the treatment effect was compared using the
generalized Cochran–Mantel–Haenszel test stratified by early CNI
type to test for raw mean scores difference. The logistic regression
model, including treatment, early CNI type, and time from
transplant to study entry, was used to analyze the proportion of
BPAR and treatment failure. For time-to-event variables, the
Kaplan–Meier method was used, and a log-rank test stratified by
early CNI type was used to compare the difference in median time
with event between treatment groups. A post hoc analysis of the
primary and several secondary end points was performed for the
subset of African-American patients.
Calculation of sample size
The primary objective of the efficacy analysis was the treatment
difference in the mean percentage change in renal function from
baseline to 12 months after randomization, as measured by GFR
(cold iothalamate). A minimum of 15% greater improvement in
renal function was expected for the CNI-withdrawal arms. A sample
size of 130 patients per arm was required assuming a s.d. s¼ 40% at
an overall significance level of a¼ 0.05 (two-sided) and a power of
1b¼ 0.85. After adjusting for a potential dropout rate of B25%,
170 patients per arm (a total of 340 patients) were planned for
enrollment.
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